0000000000997289

AUTHOR

James R. Sowers

showing 4 related works from this author

Magnesium Responsiveness to Insulin and Insulin-Like Growth Factor I in Erythrocytes from Normotensive and Hypertensive Subjects

1998

Depletion of intracellular free magnesium (Mg(i)) is a characteristic feature of insulin resistance in essential hypertension, but it is not clear to what extent low Mg(i) levels contribute to insulin resistance, result from it, or both. As insulin-like growth factor I (IGF-I) may improve insulin resistance, we investigated whether this peptide could similarly improve Mg(i) responsiveness to insulin in hypertension, and whether this effect was related to any direct IGF-I effect on Mg(i). 31P-Nuclear magnetic resonance spectroscopy was used to measure Mg(i) in erythrocytes from 13 fasting normotensive and 10 essential hypertensive subjects before and 30, 60, and 120 min after incubation with…

AdultMalemedicine.medical_specialtyErythrocytesMagnetic Resonance SpectroscopyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryEssential hypertensionBiochemistryInsulin-like growth factorEndocrinologyInsulin resistanceReference ValuesInternal medicinemedicineHumansInsulinMagnesiumInsulin-Like Growth Factor IPancreatic hormoneDose-Response Relationship Drugbusiness.industryInsulinGrowth factorBiochemistry (medical)Middle Agedmedicine.diseaseRecombinant ProteinsPathophysiologyRed blood cellEndocrinologymedicine.anatomical_structureHypertensionFemalebusinessThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Expertise

2017

Several sets of guidelines have been published recently and more are in the works. The very recent American College of Physicians/American Academy of Family Practitioners guidelines were put together by a set of authors and consultants without any expertise in the topic under discussion, that is, hypertension. Although we are not maintaining that all guidelines should be written exclusively by experts, complete lack of expertise among guideline authors is not acceptable. ispartof: Journal Of Hypertension vol:35 issue:8 pages:1564-1566 ispartof: location:Netherlands status: published

Pediatricsmedicine.medical_specialtyhypertensionPhysiologySine qua nonAlternative medicineMEDLINE030204 cardiovascular system & hematology1102 Cardiovascular Medicine And Haematology03 medical and health sciencesProfessional Competence0302 clinical medicineInternal MedicinemedicineHumansBLOOD-PRESSURE TARGETSguidelines030212 general & internal medicineSet (psychology)Societies MedicalMETAANALYSISANGIO-EDEMAOLDERMedical educationScience & Technologybusiness.industry1103 Clinical SciencesAGED 60 YEARSGuidelineProfessional competence3. Good healthPeripheral Vascular DiseaseCardiovascular System & HematologyPractice Guidelines as TopicCardiovascular System & CardiologyexpertiseINHIBITORSCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineguidelineANGIO-EDEMAJournal of Hypertension
researchProduct

Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents

2005

More than 65 million Americans are currently obese. Type 2 diabetes mellitus, frequently seen in obese subjects, affects 17 million adults in the United States, with a continuous and alarmingly increasing rate. To prevent development of diabetes in those who are at high risk, it is recommended to optimize meal planning and enhance physical activity to make sustained weight reduction possible. In addition to lifestyle changes, various oral antidiabetic agents are available, with diverse mechanisms of action. Some target defective insulin secretion (sulphonylureas, benzoic acid derivatives) or glucose absorption (glycosidase inhibitors), whereas others target insulin resistance (metformin, th…

medicine.medical_specialtyAdministration OralType 2 diabetes.PharmacologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsMetabolic SyndromeHyperplasiabusiness.industryTroglitazoneType 2 Diabetes Mellitusmedicine.diseaseMetforminTreatment OutcomeEndocrinologyBlood VesselsMetabolic syndromebusinessDiabetic AngiopathiesDyslipidemiamedicine.drugCurrent Hypertension Reports
researchProduct

Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension.

1998

Angiotension converting enzyme (ACE) inhibitors and beta-blockers have been reported to possess disparate effects on insulin sensitivity. The aim of this study was to study the effects of the selective beta-1 blocker bisoprolol and of the ACE inhibitor captopril on cellular insulin action in hypertensive individuals. After washout, 12 mild to moderate essential hypertensives were randomized in a double-blind manner to 5 mg bisoprolol daily or 25 mg captopril twice daily for 8 weeks. Erythrocyte insulin binding and insulin-stimulated tyrosine kinase (TK) activity were measured before and after therapy. Both agents decreased diastolic blood pressure significantly (bisoprolol 96.5+/-0.9 to 87.…

medicine.medical_specialtyCaptoprilmedicine.medical_treatmentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsEssential hypertensionInsulin resistanceDouble-Blind MethodInternal medicineInternal MedicinemedicineBisoprololHumansAgedbiologybusiness.industryInsulinCaptoprilAngiotensin-converting enzymeMiddle Agedmedicine.diseaseReceptor InsulinInsulin receptorEndocrinologyBisoprololACE inhibitorHypertensionbiology.proteinInsulin Resistancebusinessmedicine.drugAmerican journal of hypertension
researchProduct